Zio ECG Utilization Software (ZEUS) System vs ASSURE Wearable ECG

When choosing between the Zio ECG Utilization Software (ZEUS) System and the ASSURE Wearable ECG, physicians should consider the specific monitoring needs of their cardiac patients. Both are AI-powered, cloud-based platforms for continuous ECG monitoring, but they cater to slightly different aspects of cardiac care.

The Zio ECG Utilization Software (ZEUS) System, paired with Zio wearable monitors, excels in long-term continuous ECG data analysis for arrhythmia detection and classification, offering up to 14 days of monitoring. Its proprietary deep-learned algorithms and comprehensive end-of-wear reports, reviewed by certified cardiographic technicians, have demonstrated 99% physician agreement. This system is ideal for diagnosing infrequent or sporadic arrhythmias and for patients who may be asymptomatic or experience transient symptoms like palpitations or dizziness.

In contrast, the ASSURE Wearable ECG focuses on continuous heart rate monitoring and data collection for at-risk cardiac patients, integrated into Kestra’s broader digital healthcare platform. Key features include its SensorFit Garment with non-adhesive ECG sensors and the ASSURE Detection Algorithm with Quad Channel Processing™ and Adaptive Patient Intelligence™ for filtering motion artifacts. While it provides automatic episode storage and alert-based notifications, its primary strength lies in continuous heart rate monitoring and trend data for patients who have completed use of a Wearable Cardioverter Defibrillator (WCD) or are at risk for sudden cardiac arrest. Therefore, a physician prioritizing comprehensive, long-term arrhythmia diagnosis with detailed, technician-reviewed reports would lean towards the ZEUS System, while one focused on continuous heart rate monitoring and trend data for at-risk patients, potentially as a follow-up to WCD use, might find the ASSURE Wearable ECG more suitable.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist